Extended Data Fig. 8: mRNA-1273 elicits TH1-skewed responses compared to S-2P protein adjuvanted with alum.
From: SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
BALB/c mice (n = 6/group) were immunized at weeks 0 and 2 weeks with 1 (red) or 10 μg (purple) of mRNA-1273 or 10 μg of SARS-CoV-2 S-2P protein adjuvanted with alum hydrogel (orange). Control mice were administered PBS (grey) (n = 3). a, b, Sera were collected 2 weeks post-boost and assessed by ELISA for SARS-CoV-2 S-specific IgG1 and IgG2a. End-point titres (a) and end-point titre ratios of IgG2a to IgG1 (b) were calculated. c, d, Splenocytes were collected 4 weeks post-boost to evaluate IFN-γ, IL-4, IL-5, and IL-13 cytokine levels secreted by T cells re-stimulated with S1 (c) and S2 (d) peptide pools, measured by Luminex. In b, immunogens were compared by two-sided Mann–Whitney U-test. In c, d, for cytokines, all comparisons were compared to PBS control mice by Kruskal–Wallis ANOVA with Dunn’s multiple comparisons test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Data are presented as GMT ± geometric s.d. (a) or mean ± s.d. (b–d). Dotted line represents assay limit of detection.
